The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma
Kesang Li, Yingyi Ye, Liqin Liu, Qian Sha, Xiaolu Wang, Ting Jiao, Li Zhang, Jinyan Wang
Abstract
T cell infiltration more efficiently compared to free cGAMP. Given the upregulation of PD-L1 on tumor cells in response to STING activation, we further tested the combination therapy of LP-cGAMP and anti-PD-L1 and observed a superior antitumor effect in B16F10 and BRAF-mutated murine melanoma models. Our findings prove that targeted delivery of cGAMP can synergize PD-L1 blockade therapy in melanoma and the combinational immune therapy has a great potential to produce a long-lasting anti-tumor effect.
Topics & Concepts
BlockadeImmune checkpointMelanomaTumor microenvironmentCancer researchStingChemistryImmune systemCell cycle checkpointPharmacologyMedicineImmunologyReceptorApoptosisBiochemistryCell cycleAerospace engineeringEngineeringinterferon and immune responsesNeuroblastoma Research and TreatmentsUbiquitin and proteasome pathways